Peginterferon alfa-2b

Drug Profile

Peginterferon alfa-2b

Alternative Names: Cylatron; Interferon-alpha-2b macrogol; Intron A Peg; PEG interferon-alpha-2b; PEG-Intron; PEG-Intron A; PEG-Intron-A; Pegatron; PEGIFN; PegIntron; Pegintron; Pegtron; Pegylated IFN alfa-2b; Pegylated IFN-alpha 2b; Pegylated interferon-alpha-2b; pIFN - alpha 2b; Polyethylene glycol interferon-alpha-2b; SCH 54031; Sylatron; ViraferonPeg

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Merck & Co; Novartis; Schering-Plough; VU University Medical Center; Wistar Institute
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Malignant melanoma
  • Phase II HIV infections
  • Discontinued Chronic myeloid leukaemia; Multiple sclerosis; Polycythaemia vera; Solid tumours

Most Recent Events

  • 25 Jul 2017 Discontinued - Phase-II for Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in European Union (SC)
  • 25 Jun 2017 Merck terminates the phase II NordDutchCML009 trial as the recruitment of patients was difficult in Chronic myeloid leukaemia (Combination therapy, Second-line therapy) in Denmark, Finland, Netherlands, Norway and Sweden (SC) (NCT01866553)
  • 16 Feb 2017 Efficacy results from a phase II trial in HIV infections reported at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top